. Overview We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects. We prioritize our efforts on disease indications where there is compelling scientific rationale, no approved therapies or where there are unmet medical needs, and where there are large addressable market opportunities...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-12-12 | 2025-09-30 | 0001171843-25-007914 | EDGAR | 73K words |
| 2024-12-13 | 2024-09-30 | 0001171843-24-006946 | EDGAR | — |
| 2023-12-15 | 2023-09-30 | 0001654954-23-015632 | EDGAR | — |
| 2022-12-16 | 2022-09-30 | 0001654954-22-016633 | EDGAR | — |
| 2021-12-28 | 2021-09-30 | 0001654954-21-013551 | EDGAR | — |
| 2020-12-07 | 2020-09-30 | 0001654954-20-013236 | EDGAR | — |
| 2018-11-30 | 2018-09-30 | 0001144204-18-062614 | EDGAR | — |
| 2017-12-01 | 2017-09-30 | 0001144204-17-061791 | EDGAR | — |
| 2016-12-14 | 2016-09-30 | 0001144204-16-139528 | EDGAR | — |
| 2015-12-14 | 2015-09-30 | 0001144204-15-070753 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-13 | 2025-12-31 | 0001171843-26-000812 | EDGAR | 17K words |
| 2025-08-08 | 2025-06-30 | 0001171843-25-005236 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001171843-25-003189 | EDGAR | — |
| 2025-02-14 | 2024-12-31 | 0001171843-25-000866 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001171843-24-004651 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001654954-24-005971 | EDGAR | — |
| 2024-02-09 | 2023-12-31 | 0001654954-24-001540 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001654954-23-010380 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001654954-23-006231 | EDGAR | — |
| 2023-02-10 | 2022-12-31 | 0001654954-23-001577 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001654954-22-011208 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001654954-22-006659 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-24 | 0001171843-26-001046 | EDGAR | 2K words |
| 2026-02-13 | 0001171843-26-000810 | EDGAR | — |
| 2025-12-12 | 0001171843-25-007918 | EDGAR | — |
| 2025-12-12 | 0001171843-25-007913 | EDGAR | — |
| 2025-10-28 | 0001171843-25-006690 | EDGAR | — |
| 2025-09-30 | 0001171843-25-006188 | EDGAR | — |
| 2025-09-09 | 0001171843-25-005800 | EDGAR | — |
| 2025-08-08 | 0001171843-25-005235 | EDGAR | — |
| 2025-05-28 | 0001171843-25-003495 | EDGAR | — |
| 2025-05-14 | 0001171843-25-003183 | EDGAR | — |
315 total filings indexed. 283 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001540159 |
| Ticker | EDSA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | A1 |
| Website | https://www.edesabiotech.com |
| Listed | 2010-06-09 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report